Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells

Kumiko Taba, Yasuhiro Kuramitsu, Shomei Ryozawa, Kanako Yoshida, Toshiyuki Tanaka, Shin Ichiro Maehara, Yoshihiro Maehara, Isao Sakaida, Kazuyuki Nakamura

研究成果: ジャーナルへの寄稿学術誌査読

36 被引用数 (Scopus)


Background: Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine: Gemzar) (GEM) appears to be the only effective anticancer drug for pancreatic cancer, but it has little impact on outcome due to a high level of inherent and acquired tumor resistance. Our previous proteomic study demonstrated that the expression of three spots of heat-shock protein 27 (HSP27) was increased in GEM-resistant pancreatic cancer cells and could play a role in determining the sensitivity of pancreatic cancer to GEM. Materials and Methods and Results: In the present study, using one-dimensional and two-dimensional Western blotting, we elucidated that these three spots of HSP27 were phosphorylated in GEM-resistant pancreatic cancer cell line, KLM1-R. Conclusion: Phosphorylated HSP27 may play an important role in the resistance to GEM, and it could also be a possible biomarker for predicting the response of pancreatic cancer patients to treatment with GEM.

ジャーナルAnticancer research
出版ステータス出版済み - 7月 1 2010

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究


「Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。